TrialClinical cancer research : an official journal of the American Association for Cancer Research2024

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.

Yvette Drew et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.